Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line study

Revolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑line setting, the drug produced a median overall survival of 13.2 months.

These results validate the company’s earlier April announcement and suggest a meaningful benefit over existing options for this hard‑to‑treat cancer type. The data were presented in a study that focused on patients who had progressed after first‑line therapy.

While the report did not include comparative figures or statistical significance, the extension of survival time is considered a positive signal for investors and clinicians monitoring novel oncology candidates.

The findings add to the growing pipeline of targeted therapies aimed at addressing unmet needs in pancreatic cancer, a disease with historically poor outcomes.